Syntax Bio raises $14.4M Series A (United States, Jun 2026)
$14.4M
$14.4M Series AGenerated social card
Headline
Syntax Bio expands Series A to $14.4M, adds leadership and board members (IBB:NASDAQ) - Seeking Alpha
About
Syntax Bio is a biotechnology company focused on developing innovative therapies for genetic diseases. The company aims to address unmet medical needs through its proprietary technology platform. This funding round will help expand its leadership team and board members, enhancing its strategic direction.
Article summary
Syntax Bio expands Series A to $14.4M, adds leadership and board members (IBB:NASDAQ) Seeking Alpha
Investors
Related rounds
| Jul 10, 2026 | Ollama | $65.0M | Series B | United States |
| Jul 10, 2026 | Phonely | $22.0M | Series A | United States |
| Jul 10, 2026 | Christina Qi's startup | $97.0M | — | United States |
| Jul 10, 2026 | Zendesk | $100.0M | — | United States |